AXIAL THERAPEUTICS
LIVE

Serial Number

88641428

Owner

Axial Biotherapeutics, Inc.

Attorney

Ian W. Gillies

First Use Date

Oct 1, 2022

Filing Date

Oct 3, 2019

Add to watchlist:

No watchlists yet
View on USPTO

AXIAL THERAPEUTICS Trademark

Serial Number: 88641428 • Registration: 7037386

AXIAL THERAPEUTICS is a trademark filed by Axial Biotherapeutics, Inc. on October 3, 2019. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Axial Biotherapeutics, Inc. (6 trademarks)

9 Fourth Avenue
Waltham, MA 02451

Entity Type: 03

AXIAL THERAPEUTICS, INC. (11 trademarks)

Suite 6990
WOBURN, MA 01801

Entity Type: 03

Trademark Details

Filing Date

October 3, 2019

Registration Date

April 25, 2023

First Use Anywhere

October 1, 2022

First Use in Commerce

October 1, 2022

Published for Opposition

December 28, 2021

Goods & Services

Probiotic or microbe-targeted pharmaceutical preparations and substances for the treatment, prevention, and detection of central nervous system diseases and disorders, cancer, tumors, fibrosis, inflammation, microbe-related and microbiome-related conditions, gastrointestinal and immunological diseases, and any disease or disorder associated with intestinal permeability, or leaky gut, and amyloids; chemical, biochemical and microbial products, namely, one or more of small molecules, proteins, antibodies, nucleic acids, probiotic bacteria, probiotic bacterial cultures, and microbes being pharmaceutical preparations and substances for the treatment, prevention, and detection of central nervous system diseases and disorders, cancer, tumors, fibrosis, inflammation, microbe-related and microbiome-related conditions, gastrointestinal and immunological diseases, and any disease or disorder associated with intestinal permeability, or leaky gut, and amyloids

Chemicals, biochemicals, cells, and microbes for use in the manufacture of probiotic or microbe-targeted pharmaceutical preparations, for in vitro and in vivo scientific or research use, and for use in industry and science; chemical, biochemical and microbial products, namely, one or more of small molecules, proteins, antibodies, nucleic acids, probiotic bacteria, probiotic bacterial cultures, and microbes for the manufacture of probiotic or microbe-targeted pharmaceutical preparations for the treatment, prevention, and detection of central nervous system diseases and disorders, cancer, tumors, fibrosis, inflammation, microbe-related and microbiome-related conditions, gastrointestinal and immunological diseases, and any disease or disorder associated with intestinal permeability, or leaky gut, and amyloids

Providing medical information in the fields of diagnostic, prophylactic, and therapeutic properties of probiotic or microbe-targeted pharmaceuticals

Providing medical and scientific research information in the fields of pharmaceuticals, biochemistry, biotechnology, and clinical trials; drug discovery services; pharmaceutical research; research and development of new probiotic or microbe-targeted phamaceutical products; research in the fields of biochemistry, biotechnology, and conducting clinical trials for others

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 25, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Apr 25, 2023 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Mar 21, 2023 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Mar 18, 2023 CNPR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 22, 2023 EXRA
STATEMENT OF USE PROCESSING COMPLETE
Feb 21, 2023 SUPC
SOU EXTENSION 2 GRANTED
Feb 21, 2023 EX2G
USE AMENDMENT FILED
Feb 17, 2023 IUAF
SOU EXTENSION 2 FILED
Feb 17, 2023 EXT2
SOU TEAS EXTENSION RECEIVED
Feb 17, 2023 EEXT
TEAS STATEMENT OF USE RECEIVED
Feb 17, 2023 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 5, 2022 EXRA
SOU EXTENSION 1 GRANTED
Oct 4, 2022 EX1G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Sep 1, 2022 AITU
SOU EXTENSION 1 FILED
Aug 22, 2022 EXT1
SOU TEAS EXTENSION RECEIVED
Aug 22, 2022 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 22, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 28, 2021 NPUB
PUBLISHED FOR OPPOSITION
Dec 28, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 8, 2021 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Nov 22, 2021 PREV
ASSIGNED TO LIE
Nov 18, 2021 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 17, 2021 CNSA
ASSIGNED TO EXAMINER
Nov 15, 2021 DOCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 7, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 7, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 7, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 4, 2021 GNRN
NON-FINAL ACTION E-MAILED
Jun 4, 2021 GNRT
NON-FINAL ACTION WRITTEN
Jun 4, 2021 CNRT
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Apr 19, 2021 ZZZX
NOTICE OF ALLOWANCE CANCELLED
Mar 28, 2021 IUCN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Mar 24, 2021 ASGN
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 10, 2021 EXRA
SOU TEAS EXTENSION RECEIVED
Feb 8, 2021 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 27, 2020 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 1, 2020 NPUB
PUBLISHED FOR OPPOSITION
Sep 1, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 12, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 24, 2020 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 3, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 2, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 2, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 9, 2020 GNRN
NON-FINAL ACTION E-MAILED
Jan 9, 2020 GNRT
NON-FINAL ACTION WRITTEN
Jan 9, 2020 CNRT
NON-FINAL ACTION WRITTEN
Jan 9, 2020 CNRT
NON-FINAL ACTION WRITTEN
Jan 9, 2020 CNRT
ASSIGNED TO EXAMINER
Jan 8, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 8, 2019 NWOS
NEW APPLICATION ENTERED
Oct 7, 2019 NWAP